175 related articles for article (PubMed ID: 22696019)
21. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; Macgowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ben Ami R; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz De Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Clin Infect Dis; 2020 May; 70(11):2270-2280. PubMed ID: 31323088
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for and role of OprD protein in increasing minimal inhibitory concentrations of carbapenems in clinical isolates of Pseudomonas aeruginosa.
Hirabayashi A; Kato D; Tomita Y; Iguchi M; Yamada K; Kouyama Y; Morioka H; Tetsuka N; Yagi T
J Med Microbiol; 2017 Nov; 66(11):1562-1572. PubMed ID: 28984565
[TBL] [Abstract][Full Text] [Related]
23. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
24. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies.
Zhang Y; Chen XL; Huang AW; Liu SL; Liu WJ; Zhang N; Lu XZ
Emerg Microbes Infect; 2016 Mar; 5(3):e27. PubMed ID: 27004762
[TBL] [Abstract][Full Text] [Related]
25. Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors.
Grisaru-Soen G; Lerner-Geva L; Keller N; Berger H; Passwell JH; Barzilai A
Pediatr Infect Dis J; 2000 Oct; 19(10):959-63. PubMed ID: 11055596
[TBL] [Abstract][Full Text] [Related]
26. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
Sugimoto N; Yamagishi Y; Mikamo H
J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
[TBL] [Abstract][Full Text] [Related]
27. Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes.
Yang MA; Lee J; Choi EH; Lee HJ
J Korean Med Sci; 2011 May; 26(5):612-8. PubMed ID: 21532850
[TBL] [Abstract][Full Text] [Related]
28. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
Micek ST; Lloyd AE; Ritchie DJ; Reichley RM; Fraser VJ; Kollef MH
Antimicrob Agents Chemother; 2005 Apr; 49(4):1306-11. PubMed ID: 15793102
[TBL] [Abstract][Full Text] [Related]
29. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.
Thibault C; Lavigne J; Litalien C; Kassir N; Théorêt Y; Autmizguine J
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427292
[TBL] [Abstract][Full Text] [Related]
31. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.
Dantas RC; Ferreira ML; Gontijo-Filho PP; Ribas RM
J Med Microbiol; 2014 Dec; 63(Pt 12):1679-1687. PubMed ID: 25261066
[TBL] [Abstract][Full Text] [Related]
32. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
33. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: Mortality and prognostic factors.
Callejas-Díaz A; Fernández-Pérez C; Ramos-Martínez A; Múñez-Rubio E; Sánchez-Romero I; Vargas Núñez JA
Med Clin (Barc); 2019 Feb; 152(3):83-89. PubMed ID: 29885868
[TBL] [Abstract][Full Text] [Related]
34. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates.
El Amari EB; Chamot E; Auckenthaler R; Pechère JC; Van Delden C
Clin Infect Dis; 2001 Dec; 33(11):1859-64. PubMed ID: 11692297
[TBL] [Abstract][Full Text] [Related]
35. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
Peña C; Suarez C; Gozalo M; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2012 Mar; 56(3):1265-72. PubMed ID: 22155832
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.
Horner C; Mushtaq S; Livermore DM;
J Antimicrob Chemother; 2019 Jul; 74(7):1940-1944. PubMed ID: 31032858
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of time to positivity of blood culture in children with Pseudomonas aeruginosa bacteremia.
Xu H; Cheng J; Yu Q; Li Q; Yi Q; Luo S; Li Y; Zhang G; Tian X; Cheng D; Luo Z
BMC Infect Dis; 2020 Sep; 20(1):665. PubMed ID: 32907533
[TBL] [Abstract][Full Text] [Related]
38. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
39. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
[TBL] [Abstract][Full Text] [Related]
40. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
